11 November 2020
Quebec-based Medicago announced positive interim results from the Phase I clinical trial of its plant-derived Covid-19 vaccine candidate. The results showed that that 100% of the subjects developed significant antibody and cellular immune responses after being administered two doses of Medicago’s adjuvanted vaccine candidate.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Intas has launched Thymotas, a patented formulation of Thymoquinone that shows efficacy in fighting the SAR-CoV-2 infection. An active biological component of black cumin, Thymotas is clinically tested to be an add-on to the current standard of care for Covid-19. Various research has supported its beneficial properties, but it has been developed as a tablet for the first time by Intas.
The Medigen Vaccine Biologics Corporation and BlueWillow Biologics have collaborated to develop the S-2P-NE-01, a nasal vaccine targeting the SARS-CoV-2 virus. BlueWillow manufactures intranasal vaccines with its patented NanoVax adjuvant. Research shows that intranasal administration stimulates mucosal immunity.
Atossa Therapeutics announced positive results of its proprietary nasal spray candidate, AT-301, in its Phase I clinical study. The drug was found to be both tolerable and safe in this study when administered in single and multiple dose forms over a period of 14 days. AT-301 is being developed for recently diagnosed Covid-19 patients for at home use.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
